Tom Oomens Receives an Outstanding Score for his NIH Research Proposal


We would like to congratulate Dr. Tom Oomens on his NIH R21 application receiving an outstanding impact score of 14. The title of the proposal is: “A self-limited live RSV vaccine inducing anti- pre-fusion F antibodies” with a requested dollar amount of $357,172.

Tom is one of the project leaders in the CoBRE grant and is an Associate Professor in the Department of Pathology in CVHS, OSU. His mentor team includes Dr. Richard Eberle (OSU), Dr. Bob Welliver (OUHSC), and Dr. Mark Coggeshall (OMRF).